WEBINAR – Inhaled Dissolution: Principles, Challenges and Applications
Join us for a webinar exploring the growing role of dissolution testing in orally inhaled drug product development.
As inhaled formulations become more complex and regulatory expectations continue to evolve, dissolution testing is gaining increasing attention as a tool to support product development and equivalence assessment. However, inhaled products present unique challenges, from low dose quantities and limited media volumes to dose collection variability and the absence of compendial methods.
This session will examine the key considerations for developing robust, reproducible and discriminatory inhaled dissolution methods, including where current approaches can fall short. Attendees will also be introduced to the Inhaled Dissolution Apparatus™ IDA as an example of a purpose-built approach designed to support more consistent dose collection and dissolution testing workflows.
To register, please select a date/time by clicking on the links below:
Tuesday 28th July; 9:00-9:45am BST
Tuesday 28th July; 5:00-5:45pm BST
About the Presenter
Paul Martin | Head of Business Development
With more than a decade of experience in the inhaled drug delivery sector, Paul has a strong understanding of compendial testing requirements for orally inhaled and nasal drug products (OINDPs). He works closely with pharmaceutical scientists, formulation teams and development laboratories to support complex OINDP programmes, with expertise spanning delivered dose uniformity, aerodynamic particle size distribution measurement, aerosol characterisation, dose collection and emerging areas such as inhaled dissolution testing. He also supports organisations in interpreting evolving regulatory expectations and implementing robust, compliant OINDP test strategies, helping customers refine test set-ups, improve clinical relevance, strengthen in vitro-in vivo correlations and gain deeper insight from their data.
